Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
A young person is distressed about rapid hair loss despite using finasteride and recently starting oral minoxidil. Many suggest continuing treatment, considering dutasteride, and seeking therapy for mental health support.
The user has been using finasteride, minoxidil, microneedling, PRP, and ProCell therapy for hair loss but sees no progress after nine months. They are considering switching to dutasteride and possibly a hair transplant, with suggestions to add oral minoxidil.
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.